Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 22, 2025

Primary Completion Date

May 30, 2026

Study Completion Date

June 30, 2026

Conditions

MASLD

Interventions

DRUG

DR10624 Injection

Drug: DR10624 injection

DRUG

Placebo

Drug: Placebo

Trial Locations (2)

RECRUITING

The Affiliated Hospital of Hangzhou Normal University, Hangzhou

RECRUITING

Prince of Wales Hospital, Hong Kong

All Listed Sponsors

lead

Zhejiang Doer Biologics Co., Ltd.

INDUSTRY